Health and Healthcare
Forest Labs Sputters on Patent Expiration
Published:
Last Updated:
On a GAAP-basis, Forest Labs reported a net loss of $0.58 per share, compared with GAAP EPS of $1.04 in the third quarter of 2011. The adjusted loss excludes an upfront licensing payment of $76 million, or $0.29 per share.
The company’s CEO said:
In the third quarter of fiscal 2013, as expected, we incurred a loss resulting principally from sales lost following the expiration of Lexapro’s patent exclusivity in March 2012. The third quarter had lower sales of branded and generic Lexapro than the prior two quarters, as Lexapro declined in sales closer to its ultimately anticipated levels.
The company said that EPS for the fiscal year ending in March is now expected to be at the lower end of the company’s previously announced range of $0.45 to $0.60. Total net revenues are now forecast at $3.1 billion to $3.2 billion. The consensus estimates call for EPS of $0.25 on revenues of $3.15 billion.
Forest Labs beat back an attempt by activist investor Carl Icahn to land four board seats, surrendering only one seat in an August vote of shareholders. Icahn owns about 11% of the company’s stock.
Shares are down 5.6% in premarket trading, at $35.49 in a 52-week range of $30.90 to $38.45. Thomson Reuters had a consensus analyst price target of around $37.75 before today’s results were announced.
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.